Free Trial

Theravance Biopharma (TBPH) Competitors

Theravance Biopharma logo
$13.80 -0.11 (-0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$13.79 -0.01 (-0.07%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TBPH vs. GMTX, RXRX, CPRX, KNSA, OGN, ALVO, CNTA, IBRX, TARS, and OCUL

Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Gemini Therapeutics (GMTX), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), Tarsus Pharmaceuticals (TARS), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.

Theravance Biopharma vs. Its Competitors

Gemini Therapeutics (NASDAQ:GMTX) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Theravance Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/A-$71.87M-$1.00-60.35
Theravance Biopharma$77.21M9.00-$56.42M$0.2457.50

In the previous week, Theravance Biopharma had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Theravance Biopharma and 0 mentions for Gemini Therapeutics. Theravance Biopharma's average media sentiment score of 0.05 beat Gemini Therapeutics' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Gemini Therapeutics Neutral
Theravance Biopharma Neutral

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Theravance Biopharma has a net margin of 16.88% compared to Gemini Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 6.93% beat Gemini Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gemini TherapeuticsN/A -38.78% -35.88%
Theravance Biopharma 16.88%6.93%3.52%

Theravance Biopharma has a consensus price target of $21.33, suggesting a potential upside of 54.59%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Gemini Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gemini Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Theravance Biopharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500.

Summary

Theravance Biopharma beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TBPH vs. The Competition

MetricTheravance BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$694.98M$2.78B$5.75B$9.73B
Dividend YieldN/A1.67%4.40%4.10%
P/E Ratio57.5022.2430.2525.89
Price / Sales9.00749.20474.39123.10
Price / CashN/A26.0925.7828.79
Price / Book3.875.539.426.00
Net Income-$56.42M$31.83M$3.27B$265.29M
7 Day Performance1.40%1.07%2.08%2.59%
1 Month Performance25.11%0.83%3.63%0.98%
1 Year Performance70.58%7.24%30.13%18.75%

Theravance Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TBPH
Theravance Biopharma
2.0912 of 5 stars
$13.80
-0.8%
$21.33
+54.6%
+71.9%$694.98M$77.21M57.50110High Trading Volume
GMTX
Gemini Therapeutics
N/A$59.86
-1.4%
N/A+22.1%$2.59BN/A-59.8630
RXRX
Recursion Pharmaceuticals
2.3464 of 5 stars
$5.52
-4.3%
$7.00
+26.8%
-36.7%$2.51B$58.84M-3.10400
CPRX
Catalyst Pharmaceuticals
4.8976 of 5 stars
$20.23
flat
$33.20
+64.1%
+3.7%$2.48B$491.73M12.2680News Coverage
Positive News
Gap Up
KNSA
Kiniksa Pharmaceuticals International
2.6092 of 5 stars
$33.72
+1.0%
$41.17
+22.1%
+23.3%$2.47B$423.24M843.21220
OGN
Organon & Co.
4.6477 of 5 stars
$9.27
-1.8%
$18.00
+94.2%
-57.9%$2.45B$6.40B3.454,000Positive News
ALVO
Alvotech
2.7424 of 5 stars
$9.00
+12.2%
$14.00
+55.6%
-28.9%$2.42B$491.98M39.131,032High Trading Volume
CNTA
Centessa Pharmaceuticals
2.3548 of 5 stars
$17.59
-2.5%
$28.10
+59.7%
+32.4%$2.42B$6.85M-9.83200
IBRX
ImmunityBio
2.5064 of 5 stars
$2.43
-4.7%
$10.75
+342.4%
-45.6%$2.41B$14.74M-5.06590
TARS
Tarsus Pharmaceuticals
1.8629 of 5 stars
$54.61
+0.7%
$66.67
+22.1%
+124.2%$2.29B$182.95M-23.4450News Coverage
Positive News
OCUL
Ocular Therapeutix
4.0529 of 5 stars
$12.31
-2.5%
$17.20
+39.7%
+35.0%$2.20B$63.72M-9.62230Positive News

Related Companies and Tools


This page (NASDAQ:TBPH) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners